System and methods for performing saliva-based diagnostic screenings
US-2024420847-A1 · Dec 19, 2024 · US
US12442817B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12442817-B2 |
| Application number | US-202017641402-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 10, 2020 |
| Priority date | Sep 12, 2019 |
| Publication date | Oct 14, 2025 |
| Grant date | Oct 14, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of monitoring acute hepatopancreatic necrosis disease in shrimp is disclosed. More specifically, detection of the presence of alkaline phosphatase Phox enzyme, or, of the PiRAVP and/or the PirBVP toxins of acute hepatopancreatic necrosis disease-causing Vibrio parahaemolyticus correlates with non-virulence or virulence, respectively, of the bacterium is disclosed. Hence, an assay capable of detecting the Phox enzyme and/or the toxins could be very useful to monitor the disease in shrimp.
Opening claim text (preview).
The invention claimed is: 1. A method of phenotyping Vibrio parahaemolyticus as non-virulent, the method comprising: providing a sample comprising shrimp culture water; utilizing antibodies or fragments thereof that bind to alkaline phosphatase Phox enzyme of V. parahaemolyticus to phenotype the V. parahaemolyticus as non-virulent; and culturing the shrimp without disease-mitigation treatment if the V. parahaemolyticus are phenotyped as non-virulent. 2. The method according to claim 1 , whereby acute hepatopancreatic necrosis disease in shrimp is monitored. 3. An assay comprising: antibodies or fragments thereof that bind to the alkaline phosphatase Phox enzyme of Vibrio parahaemolyticus. 4. A method of using the assay according to claim 3 to phenotype V. parahaemolyticus as non-virulent or as virulent, the method comprising: interacting the assay with a sample. 5. The assay according to claim 4 , wherein the assay is a lateral flow immunochromatographic assay or an enzyme-linked immunosorbent assay. 6. A process of phenotyping Vibrio parahaemolyticus as non-virulent, the process comprising: providing a sample comprising shrimp culture water; bringing the sample into contact with antibodies or fragments thereof that bind to alkaline phosphatase Phox enzyme of V. parahaemolyticus; determining whether the alkaline phosphatase Phox enzyme of V. parahaemolyticus is present in the sample; classifying the V. parahaemolyticus s non-virulent when the alkaline phosphatase Phox enzyme is present in the sample; and culturing the shrimp without disease-mitigation treatment upon classification of the V. parahaemolyticus as non-virulent. 7. The method according to claim 4 , wherein the assay is a lateral flow immunochromatographic assay or an enzyme-linked immunosorbent assay.
acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4) · CPC title
from Vibrionaceae (F) · CPC title
for enzymes or isoenzymes · CPC title
Bacteria · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.